EvodiaBio ApS: Financial statements 2024
CVR: 42569283
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
EvodiaBio ApS (CVR 42569283) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -10,008,821 and a net result of DKK -21,106,598 compared with DKK -14,056,555 the year before. Equity in the 2024 report amounted to DKK 52,423,684. The solvency ratio was 95.2%. The company had 17 employees in the financial year.
- Gross Profit
- DKK -10,008,821
- Profit/Loss
- DKK -21,106,598
- Equity
- DKK 52,423,684
- Total Assets
- DKK 55,043,059
- Employees
- 17
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -10 mio. | -21.1 mio. | 52.4 mio. | 17 |
| 2023 | - | -9.9 mio. | -14.1 mio. | 23.6 mio. | 10 |
| 2022 | - | -2.9 mio. | -6.3 mio. | 37.7 mio. | 7 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
EvodiaBio ApS has published its annual report for 2023. Gross profit came to DKK -9,941,780, and the net result was DKK -14,056,555.
As of May 17, 2024, Johan Bitsch Nielsen has joined the board of directors of EvodiaBio ApS.
As of May 17, 2024, Bart Van Hooland has left the board of directors of EvodiaBio ApS.
As of May 17, 2024, BII Holdings A/S is registered as an owner of EvodiaBio ApS with an ownership share of 5%.
As of May 17, 2024, is registered as an owner of EvodiaBio ApS with an ownership share of 5%.
About EvodiaBio ApS
EvodiaBio ApS is a Danish company of the type Anpartsselskab based in Rødovre, founded in 2021. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Camilla Benedicte Kloss Fenneberg. The board consists of Jarne Elleholm (chair), Andreas Helmut Fibig, Anne Françoise Véronique Cabotin and Flemming Besenbacher. The company's owners include Jarne Elleholm, BII Holdings A/S and FormanBiotech Holding ApS. According to the 2025 annual report, the company had an average of 23 employees. In 2025, the company reported a gross profit of DKK -8,437,110 and a net result of DKK -26,798,122 compared with DKK -21,106,598 the year before. Equity in the 2025 report amounted to DKK 68,626,121.